parallel randomized trial

S002906

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Metabolic dysfunction associated steatotic liver disease or steatohepatitisS002906

Design

Randomized: 31
Start year: 2017
Treatment: 12 weeks, follow-up 24 weeks
Countries: United Kingdom (1 sites)
Sponsor: University of Oxford (mixed)
Eligibility: age 18 to 75; progressed MASLD by imaging with raised ALT, biopsy or stiffness above 8 kPa; no type 2 diabetes

Conduct and analysis

Blinding: open label
Sequence generation: computer
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: completers
Missing data: completers only

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Lifestyle intervention (randomized arm) Lifestyle	lifestyle: intensive		14	14
A2	Liraglutide 1.8 mg subcutaneous once daily Liraglutide	lifestyle: not reported		15	15

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Lifestyle intervention (randomized arm) A1	Liraglutide 1.8 mg subcutaneous once daily A2
age	mean (years)	48	48
age	se (years)	4	4
bmi	mean (kg/m2)	36.4	35.7
bmi	se (kg/m2)	1.5	1.7
hba1c	mean (mmol/mol)	37	39
hba1c	se (mmol/mol)	1	1
other male	percent	50.0	53.3
sbp	mean (mmHg)	136	133
sbp	se (mmHg)	4	3
weight	mean (kg)	104.2	106.9
weight	se (kg)	5.8	5.6